Role of circulating-tumor DNA in the early-stage non-small cell lung carcinoma as a predictive biomarker

Lung cancer is one of the most common solid malignancies. Tissue biopsy is the standard method for accurately diagnosing lung and many other malignancies over decades. However, molecular profiling of tumors leads to establishing a new horizon in the field of precision medicine, which has now entered...

Full description

Saved in:
Bibliographic Details
Published in:Pathology, research and practice research and practice, 2023-05, Vol.245, p.154455-154455, Article 154455
Main Authors: Khan, Saqib Raza, Scheffler, Matthias, Soomar, Salman Muhammad, Rashid, Yasmin Abdul, Moosajee, Munira, Ahmad, Aamir, Raza, Afsheen, Uddin, Shahab
Format: Article
Language:English
Subjects:
Biomarker
Biomarkers, Tumor - genetics
Carcinoma, Non-Small-Cell Lung - pathology
Circulating Tumor DNA - genetics
Circulating Tumor DNA - therapeutic use
CtDNA
Humans
Lung cancer
Lung Neoplasms - pathology
Precision medicine
Small Cell Lung Carcinoma
Treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lung cancer is one of the most common solid malignancies. Tissue biopsy is the standard method for accurately diagnosing lung and many other malignancies over decades. However, molecular profiling of tumors leads to establishing a new horizon in the field of precision medicine, which has now entered the mainstream in clinical practice. In this context, a minimally invasive complementary method has been proposed as a liquid biopsy (LB) which is a blood-based test that is gaining popularity as it provides the opportunity to test genotypes in a unique, less invasive manner. Circulating tumor cells (CTC) captivating the Circulating-tumor DNA (Ct-DNA) are often present in the blood of lung cancer patients and are the fundamental concept behind LB. There are multiple clinical uses of Ct-DNA, including its role in prognostic and therapeutic purposes. The treatment of lung cancer has drastically evolved over time. Therefore, this review article mainly focuses on the current literature on circulating tumor DNA and its clinical implications and future goals in non-small cell lung cancer.
ISSN:0344-0338
1618-0631
DOI:10.1016/j.prp.2023.154455